Soonmyung Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Soonmyung Hwang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Parul Agarwal
Department of Population Science and Health Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA
3 shared publicationsBenjamin Kummer
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publicationsBenjamin R. Kummer
Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications- Efrat Abramson
Interdepartmental Neuroscience Program, Yale University School of Medicine, Yale University, New Haven, CT 06510, USA
2 shared publications Margaret H. Downes
Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications- Michael Davin Kornberg
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA
2 shared publications
Latest Publications
- 16 November 2026
- Published by SAGE Publications in Telemedicine and e-Health
Neurology eConsult Content and Adoption of Consultant Recommendations at a Large Academic Health System: A Retrospective Cohort Study
Introduction: Interprofessional consultations (“eConsults”) can improve access to specialist expertise, but the content of neurology eConsults and rates of consultant recommendation adoption remain under-characterized. Methods: We conducted a retrospective cohort study of neurology eConsults submitted at the Mount Sinai Health System between August 2020 and July 2024, excluding canceled, unanswered, and duplicate eConsult submissions. Two reviewers independently categorized consultative questions and consultant recommendations. The primary outcome was adoption of at least one consultant recommendation within 12 months of the eConsult submission. Secondary outcomes were adoption by recommendation type. Multivariable logistic regression analysis identified factors associated with overall recommendation adoption. Results: We identified 771 eConsults comprising 872 consultative questions for 736 patients (median age 56 years; 67.7% female). The most common questions concerned diagnostic work-up ( n = 226, 29.3%), initial treatment or medication choice ( n = 123, 16.0%), and interpretation of the clinical presentation ( n = 88, 11.4%). Consultants most frequently recommended an in-person neurology evaluation ( n = 322, 41.8%) and neuroimaging ( n = 244, 31.6%). Overall, at least one recommendation was adopted in 408 of 567 eConsults (72.0%). Recommendations for neuroimaging, medications, and laboratory testing were adopted in 55.7% ( n = 136/244), 72.7% ( n = 88/121), and 76.0% ( n = 38/50) of applicable eConsults, respectively, and 66.5% ( n = 214/322) of patients recommended for in-person evaluation completed a neurology visit within 1 year. In multivariable analysis, adoption of at least one recommendation was more likely when consultants recommended addition of a medication [adjusted odds ratio (aOR) = 3.41, 95% CI: 1.71–6.82] or an in-person neurology evaluation (aOR = 2.45, 95% CI: 1.41–4.26). Discussion: Neurology eConsults addressed a broad range of diagnostic and management questions, and most eConsults with a recommendation had at least one adopted within 12 months. Adoption was lowest for recommendations requiring an additional encounter, and one-third of patients were advised to see a neurologist and did not complete a visit within 1 year, highlighting a gap in continuity of specialty care.
- 16 November 2026
- Published by SAGE Publications in Telemedicine and e-Health
Neurology eConsult Content and Adoption of Consultant Recommendations at a Large Academic Health System: A Retrospective Cohort Study
Introduction: Interprofessional consultations (“eConsults”) can improve access to specialist expertise, but the content of neurology eConsults and rates of consultant recommendation adoption remain under-characterized. Methods: We conducted a retrospective cohort study of neurology eConsults submitted at the Mount Sinai Health System between August 2020 and July 2024, excluding canceled, unanswered, and duplicate eConsult submissions. Two reviewers independently categorized consultative questions and consultant recommendations. The primary outcome was adoption of at least one consultant recommendation within 12 months of the eConsult submission. Secondary outcomes were adoption by recommendation type. Multivariable logistic regression analysis identified factors associated with overall recommendation adoption. Results: We identified 771 eConsults comprising 872 consultative questions for 736 patients (median age 56 years; 67.7% female). The most common questions concerned diagnostic work-up ( n = 226, 29.3%), initial treatment or medication choice ( n = 123, 16.0%), and interpretation of the clinical presentation ( n = 88, 11.4%). Consultants most frequently recommended an in-person neurology evaluation ( n = 322, 41.8%) and neuroimaging ( n = 244, 31.6%). Overall, at least one recommendation was adopted in 408 of 567 eConsults (72.0%). Recommendations for neuroimaging, medications, and laboratory testing were adopted in 55.7% ( n = 136/244), 72.7% ( n = 88/121), and 76.0% ( n = 38/50) of applicable eConsults, respectively, and 66.5% ( n = 214/322) of patients recommended for in-person evaluation completed a neurology visit within 1 year. In multivariable analysis, adoption of at least one recommendation was more likely when consultants recommended addition of a medication [adjusted odds ratio (aOR) = 3.41, 95% CI: 1.71–6.82] or an in-person neurology evaluation (aOR = 2.45, 95% CI: 1.41–4.26). Discussion: Neurology eConsults addressed a broad range of diagnostic and management questions, and most eConsults with a recommendation had at least one adopted within 12 months. Adoption was lowest for recommendations requiring an additional encounter, and one-third of patients were advised to see a neurologist and did not complete a visit within 1 year, highlighting a gap in continuity of specialty care.
- 23 September 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 29-36
Financial distress among individuals with epilepsy: Insights from a nationwide survey analysis
- 23 September 2025
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 133, 29-36
Financial distress among individuals with epilepsy: Insights from a nationwide survey analysis
- 30 April 2025
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 31 (5) , 614-623
Health Care Utilization Patterns Associated with eConsults for Headache: Insights from an Urban Academic Medical Center
Introduction: : Interprofessional electronic consultations (eConsults) can reduce health care utilization and improve access to specialty care. However, health care utilization and access impacts of eConsults for headache disorders remain incompletely characterized. Methods: : We conducted a retrospective, 1:3-matched cohort study comparing patients referred for in-person headache evaluations to patients who had a headache-related eConsult. The cohorts were propensity score-matched by age, sex, race, preferred language, provider specialty, insurance status, and medical comorbidities. Our primary outcome was the presence of one or more headache-related ambulatory encounters in the 12 months following the index referral date. We used univariable and conditional logistic regression models to ascertain the associations between referral type and outcome. Results: : We identified 74 and 222 patients with eConsult and in-person referrals, respectively. Over the follow-up period, the proportion of patients with the primary outcome was significantly greater in the eConsult cohort than the in-person cohort (46.0% vs. 43.2%, p < 0.0001). A greater proportion of the in-person cohort had one or more ambulatory headache encounters in the 12 months preceding their referral than the eConsult cohort (10.8% vs. 5.4%, p < 0.0001). In the adjusted analysis, eConsult usage was not associated with significantly increased odds of the primary outcome (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 0.6–2.0, p = 0.71), although patients with one or more ambulatory neurology encounters in the preceding 12 months had significantly increased odds of the primary outcome (aOR 3.1, 95% CI 1.2–7.9, p = 0.015). Conclusion: : Compared to in-person referrals, eConsult use for headache was not associated with significantly increased odds of having subsequent ambulatory headache-related encounters.
- 30 April 2025
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 31 (5) , 614-623
Health Care Utilization Patterns Associated with eConsults for Headache: Insights from an Urban Academic Medical Center
Introduction: : Interprofessional electronic consultations (eConsults) can reduce health care utilization and improve access to specialty care. However, health care utilization and access impacts of eConsults for headache disorders remain incompletely characterized. Methods: : We conducted a retrospective, 1:3-matched cohort study comparing patients referred for in-person headache evaluations to patients who had a headache-related eConsult. The cohorts were propensity score-matched by age, sex, race, preferred language, provider specialty, insurance status, and medical comorbidities. Our primary outcome was the presence of one or more headache-related ambulatory encounters in the 12 months following the index referral date. We used univariable and conditional logistic regression models to ascertain the associations between referral type and outcome. Results: : We identified 74 and 222 patients with eConsult and in-person referrals, respectively. Over the follow-up period, the proportion of patients with the primary outcome was significantly greater in the eConsult cohort than the in-person cohort (46.0% vs. 43.2%, p < 0.0001). A greater proportion of the in-person cohort had one or more ambulatory headache encounters in the 12 months preceding their referral than the eConsult cohort (10.8% vs. 5.4%, p < 0.0001). In the adjusted analysis, eConsult usage was not associated with significantly increased odds of the primary outcome (adjusted odds ratio [aOR] 1.1, 95% confidence interval [CI] 0.6–2.0, p = 0.71), although patients with one or more ambulatory neurology encounters in the preceding 12 months had significantly increased odds of the primary outcome (aOR 3.1, 95% CI 1.2–7.9, p = 0.015). Conclusion: : Compared to in-person referrals, eConsult use for headache was not associated with significantly increased odds of having subsequent ambulatory headache-related encounters.
- 10 January 2025
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 31 (1) , 59-65
Utilization of Remote Patient Monitoring for Neurological Disorders: A Nationwide Analysis of Administrative Claims Data
Introduction: : The use of remote patient monitoring (RPM) services for neurological disorders remains understudied, particularly in the context of newer billing codes introduced before the COVID-19 pandemic. Methods: : This retrospective cohort study utilized data from commercial and Medicare employer-sponsored administrative claims between January 1, 2019, to December 31, 2021. The study population included all patients with at least one qualifying RPM-related Current Procedural Terminology (CPT) code for a neurological disorder, separated into first-generation (CPT 99091) codes and second-generation (CPT 99453, 99454, 99457, 99458) code cohorts. We compared patient and encounter characteristics between both cohorts. Results: : We identified 27,756 encounters attributable to 11,326 patients who received RPM services for neurological disorders, of whom 5,785 (51.1%) received RPM via second-generation billing codes, 3,941 (34.8%) were female, 6,712 (59.3%) were between 45 and 64 years old, and 10,488 (92.6%) had a primary diagnosis of sleep–wake disorder. The second-generation cohort was significantly more likely to be female (41.5% vs. 27.8%, p < 0.001), be of age 65 or older (15.7% vs. 7.1%, p < 0.001), and reside in urban areas (93.4% vs. 87.6%, p < 0.001) than the first-generation cohort. Patients in the second-generation cohort were more likely to receive RPM in office settings (86.3% vs. 62.5%, p < 0.001), by physicians (77.0% vs. 40.3%, p < 0.001), and less likely for sleep–wake disorders (87.9% vs. 97.5%, p < 0.001) than the first-generation cohort. Patients who received RPM from physicians were most often evaluated by pulmonologists (31.4%). Discussion: : In this commercially insured patient population receiving RPM for neurological disorders, we found that sleep–wake disorders and non-neurologists were over-represented.
- 10 January 2025
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 31 (1) , 59-65
Utilization of Remote Patient Monitoring for Neurological Disorders: A Nationwide Analysis of Administrative Claims Data
Introduction: : The use of remote patient monitoring (RPM) services for neurological disorders remains understudied, particularly in the context of newer billing codes introduced before the COVID-19 pandemic. Methods: : This retrospective cohort study utilized data from commercial and Medicare employer-sponsored administrative claims between January 1, 2019, to December 31, 2021. The study population included all patients with at least one qualifying RPM-related Current Procedural Terminology (CPT) code for a neurological disorder, separated into first-generation (CPT 99091) codes and second-generation (CPT 99453, 99454, 99457, 99458) code cohorts. We compared patient and encounter characteristics between both cohorts. Results: : We identified 27,756 encounters attributable to 11,326 patients who received RPM services for neurological disorders, of whom 5,785 (51.1%) received RPM via second-generation billing codes, 3,941 (34.8%) were female, 6,712 (59.3%) were between 45 and 64 years old, and 10,488 (92.6%) had a primary diagnosis of sleep–wake disorder. The second-generation cohort was significantly more likely to be female (41.5% vs. 27.8%, p < 0.001), be of age 65 or older (15.7% vs. 7.1%, p < 0.001), and reside in urban areas (93.4% vs. 87.6%, p < 0.001) than the first-generation cohort. Patients in the second-generation cohort were more likely to receive RPM in office settings (86.3% vs. 62.5%, p < 0.001), by physicians (77.0% vs. 40.3%, p < 0.001), and less likely for sleep–wake disorders (87.9% vs. 97.5%, p < 0.001) than the first-generation cohort. Patients who received RPM from physicians were most often evaluated by pulmonologists (31.4%). Discussion: : In this commercially insured patient population receiving RPM for neurological disorders, we found that sleep–wake disorders and non-neurologists were over-represented.
- 8 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (780) , eadk3434
The protein kinase C modulator bryostatin-1 therapeutically targets microglia to attenuate neuroinflammation and promote remyelination
In multiple sclerosis (MS), microglia and macrophages within the central nervous system (CNS) play an important role in determining the balance among demyelination, neurodegeneration, and myelin repair. Phagocytic and regenerative functions of these CNS innate immune cells support remyelination, whereas chronic and maladaptive inflammatory activation promotes lesion expansion and disability, particularly in the progressive forms of MS. No currently approved drugs convincingly target microglia and macrophages within the CNS, contributing to the lack of therapies aimed at promoting remyelination and slowing disease progression for individuals with MS. Here, we found that the protein kinase C (PKC)–modulating drug bryostatin-1 (bryo-1), a CNS-penetrant compound with an established human safety profile, shifts the transcriptional programs of microglia and CNS-associated macrophages from a proinflammatory phenotype to a regenerative phenotype in vitro and in vivo. Treatment of microglia with bryo-1 stimulated scavenger pathways, phagocytosis, and secretion of factors that prevented the activation of neuroinflammatory reactive astrocytes while also promoting neuroaxonal health and oligodendrocyte differentiation. In line with these findings, systemic treatment of mice with bryo-1 augmented remyelination after a focal demyelinating injury. Our results demonstrate the potential of bryo-1 and possibly a wider class of PKC modulators as myelin-regenerative and supportive agents in MS and other neurologic diseases.
- 8 January 2025
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 17 (780) , eadk3434
The protein kinase C modulator bryostatin-1 therapeutically targets microglia to attenuate neuroinflammation and promote remyelination
In multiple sclerosis (MS), microglia and macrophages within the central nervous system (CNS) play an important role in determining the balance among demyelination, neurodegeneration, and myelin repair. Phagocytic and regenerative functions of these CNS innate immune cells support remyelination, whereas chronic and maladaptive inflammatory activation promotes lesion expansion and disability, particularly in the progressive forms of MS. No currently approved drugs convincingly target microglia and macrophages within the CNS, contributing to the lack of therapies aimed at promoting remyelination and slowing disease progression for individuals with MS. Here, we found that the protein kinase C (PKC)–modulating drug bryostatin-1 (bryo-1), a CNS-penetrant compound with an established human safety profile, shifts the transcriptional programs of microglia and CNS-associated macrophages from a proinflammatory phenotype to a regenerative phenotype in vitro and in vivo. Treatment of microglia with bryo-1 stimulated scavenger pathways, phagocytosis, and secretion of factors that prevented the activation of neuroinflammatory reactive astrocytes while also promoting neuroaxonal health and oligodendrocyte differentiation. In line with these findings, systemic treatment of mice with bryo-1 augmented remyelination after a focal demyelinating injury. Our results demonstrate the potential of bryo-1 and possibly a wider class of PKC modulators as myelin-regenerative and supportive agents in MS and other neurologic diseases.
- 16 July 2024
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 30 (7) , 1842-1847
Descriptive Analysis of Patients Receiving Outpatient eConsults for Neurological Disorders in the United States
Introduction: Interprofessional consultations (“eConsults”), which facilitate asynchronous specialist consultations, remain understudied in neurological disorders. We aimed to describe the patient population receiving eConsult services for neurological disorders nationwide and to conduct a comparative analysis between rural and urban patients within this eConsult cohort. Methods: We analyzed a dataset of U.S. outpatient claims from employer-sponsored commercial and Medicare plans. Using standardized mean differences, we compared clinical and sociodemographic patient characteristics between urban and rural patients within the eConsult group. Results: We identified 1,374 patients who had an eConsult order for a neurological disorder. Overall eConsult volume increased by 548.5% between 2019 and 2021. A majority of the cohort were aged 65 years or older (23.7%), had an eConsult order in 2021 (52.4%), and live in an urban area (90.4%). The primary diagnosis for our cohort was likely to be a sleep-wake disorder (21.9%), cerebrovascular disease (14.3%), neurological sign or symptom (14.2%), or headache (13.7%). In the secondary analysis, rural eConsult patients exhibited higher rates of primary diagnoses for traumatic brain injury, neuroophthalmic disorders, or neuropathy than their urban counterparts. Discussion: In this national sample of commercially insured patients, the utilization of eConsults for neurological conditions increased nationwide since 2019, especially for patients living in rural areas.
- 16 July 2024
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 30 (7) , 1842-1847
Descriptive Analysis of Patients Receiving Outpatient eConsults for Neurological Disorders in the United States
Introduction: Interprofessional consultations (“eConsults”), which facilitate asynchronous specialist consultations, remain understudied in neurological disorders. We aimed to describe the patient population receiving eConsult services for neurological disorders nationwide and to conduct a comparative analysis between rural and urban patients within this eConsult cohort. Methods: We analyzed a dataset of U.S. outpatient claims from employer-sponsored commercial and Medicare plans. Using standardized mean differences, we compared clinical and sociodemographic patient characteristics between urban and rural patients within the eConsult group. Results: We identified 1,374 patients who had an eConsult order for a neurological disorder. Overall eConsult volume increased by 548.5% between 2019 and 2021. A majority of the cohort were aged 65 years or older (23.7%), had an eConsult order in 2021 (52.4%), and live in an urban area (90.4%). The primary diagnosis for our cohort was likely to be a sleep-wake disorder (21.9%), cerebrovascular disease (14.3%), neurological sign or symptom (14.2%), or headache (13.7%). In the secondary analysis, rural eConsult patients exhibited higher rates of primary diagnoses for traumatic brain injury, neuroophthalmic disorders, or neuropathy than their urban counterparts. Discussion: In this national sample of commercially insured patients, the utilization of eConsults for neurological conditions increased nationwide since 2019, especially for patients living in rural areas.
- 19 January 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (4) , 537-545.e4
Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation
- 19 January 2021
- Published by Elsevier in Cell Chemical Biology
- Vol. 28 (4) , 537-545.e4
Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation